Fernando Arias-Mendoza, MD, PhD

Translational Researcher

  1. PUIC-UNAM-1982-02
    National Autonomous University of Mexico
    In Vivo Murine Liver Metabolism Studies by NMR at 9.4 Tesla. International Training Program working at the Department of Molecular Biochemistry & Biophysics, Yale University, Connecticut, USA. 1982-1985
  2. 1F05TW03346
    Fogarty International Center, NIH
    In Situ Murine Liver Metabolism Studies by NMR in a Large Bore Magnet at 2.0 Tesla. Public Health Service International Research Fellow Training Program working at the Molecular Biophysics & Biochemistry Department, Yale University, Connecticut USA. 1983-1985
  1. NSR-AIMF570214
    NatIonal System of Researchers, Mexico City, Mexico, 1988-1990, Principal Investigator
    Clinical Studies on Inborn Errors of Metabolism. Research grant award to study biological samples of children with Inborn Errors of Metabolism using different screening and diagnostic techniques, including MR spectroscopy.
  2. U01CA0062556
    National Cancer Institute, NIH, 1995-2006, Co-Principal Investigator from 1999
    Predicting Human Tumor Response by 31P MR Spectroscopy. To test if tumor variables obtained using 31P MRS predicted sensitivity or resistance of human cancer to treatment. The final results suggested that the pretreatment value of phosphomonoesters normalized to nucleotide triphosphates (PME/NTP) could predict response to treatment in non-Hodgkin’s lymphomas.
  3. 5P01CA41078
    National Cancer Institute, NIH, 1997-2005, Principal Investigator of Project II
    NMR Studies of Human Cancer. Program Project Grant with the major goals to combine in vivo, ex vivo, and in vitro, methodological strategies with emphasis on MRS to study cancer metabolism in humans in a multidisciplinary fashion.
  4. 5R01CA118559
    National Cancer Institute, NIH, 2007-2014, Principal Investigator from 2010
    In Vivo 31P & 1H MR Spectroscopy Studies of non-Hodgkin’s Lymphomas. Cooperative program with the aim to corroborate if the tumor PME/NTP value measured by 31P MR spectroscopy is correlated with treatment outcome in an independent, larger cancer patient cohort. We also seek to extend these findings by investigating absolute choline levels by 1H MRS and to follow up on initial indications that the significance of the correlation between PME/NTP and treatment outcome is widely applicable to other forms of lymphoma.
  5. 5R21CA152858
    National Cancer Institute, NIH, 2010-2013, Principal Investigator
    Predicting Outcome of Experimental Therapy in Lymphomas by 31P & 1H MR Spectroscopy. The aim of this proposal was to demonstrate if 31P and 1H MR Spectroscopy could provide early and objective predictive measures of treatment response in recurrent patients afflicted with non-Hodgkin’s lymphoma, who will be treated with non-standard, experimental therapy.

other past support as principal investigator:

  1. 1R43NS037273
    National Institute of Neurological Disorders & Stroke, NIH, 1998-1999, PI, R. Srinivasan
    Dual-Tuned Probe for MRI/MRS of the Human Brain. The aim of this proposal was to build a dual-tuned (31P/1H) probe for the study of human brain using MRI and multinuclear spectroscopic imaging with similar fields of views for both nuclei.
  2. 1R44NS037273
    National Institute of Neurological Disorders & Stroke, NIH, 2000-2002, PI, R. Srinivasan
    Dual-Tuned Probe for MRI/MRS of the Human Brain. The aim of this proposal was the continuation of research program 1R43NS037273 to build dual-tuned coils.
  1. 5P01HD032062
    National Institute of Child Health and Human Development, NIH, 2004-2015, PI D.DeVivo/S DiMauro
    Mitochondrial Encephalomyopathies & Mental Retardation. This program focused on mitochondrial encephalomyopathies and mental retardation. In Project 1, patients were enrolled for long-term evaluation as part of a natural history study, which include MR imaging and spectroscopy of the brain and muscle.
  2. 5R01DK64773
    National Institute of Child Health and Human Development, NIH, 2008-2013, PI, R. Liebel
    Leptin in Human Energy & Neuroendocrine Homeostasis. The major goal of this project was to characterize the effects of maintenance of reduced body weight on systemic energetics and on specific neuroendocrine and autonomic axes related to energy metabolism. The protocol examined the effects on these parameters of administration of exogenous leptin.
  3. R01DK064720
    National Institute of Diabetes and Digestive and Kidney Disease, NIH, 2009-2014, PI, P. Freda
    New Approaches to the Evaluation and Treatment of Acromegaly. The major goal of this project was to integrally study patients with acromegaly. We are utilizing modern biochemical and imaging methods including whole body MRI and 1H MRSI of the liver and muscle prior and after therapy in a uniquely large ongoing prospective acromegaly patient cohort.
  4. 5R01HD056103
    National Institute of Child Health and Human Development, NIH, 2010-2015, PI, M. Hirano
    Molecular Pathogenesis and Treatment of MNGIE. The major goal of this project was to characterize a mouse model of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) including in vivo MR imaging and MR spectroscopy of the mouse brain.
  5. PG004259
    Alzheimer’s Drug Discovery Fund, 2012-2013, PI, L. Honig
    Magnetic Resonance Spectroscopy (MRS) to Assess Progression of Alzheimer Disease. The aim of this project was to study in a group of patients with Alzheimer Disease the anterior cingulate cortex, the premotor cortex, the occipital cortex, and the parietal subcortical white matter to assess slope of temporal decline of N-acetyl aspartate, choline, myoinositol, and creatine measured by MRS.
  6. 1R01CA161404
    National Cancer Institute, NIH, 2012-2017, PI, J. Bruce
    Chronic Convection-Enhanced Delivery (CED) of Topotecan for Glioblastoma. The aim of this proposal was to critically test an innovative implantable catheter and pump system for delivering chemotherapy (topotecan) directly into the tumor for over extended time periods to avoid the side effects associated with standard oral or intravenous delivery.
  7. 1U54CA168512
    National Cancer Institute, NIH, 2012-2017, PI, R. Pollock
    SARC Sarcoma SPORE, Quantitative Imaging Biomarkers for Assessing Response to Therapy. The goal was to develop imaging biomarkers of apoptosis, angiogenesis, and hypoxia that will predict therapeutic efficacy in sarcoma to test that functional and molecular imaging of these tumor characteristics will enable early identification of therapeutic efficacy of molecular agents that target these processes.
  8. JMDF S/N
    JS McDonell Foundation, 2013-2015, PI, A. Lassman
    Phase II Clinical Trial of Perifosine plus Temsirolimus for Recurrent Glioblastoma with Tissue and Imaging Correlates of Response. The program aimed to recruit patients with glioblastoma mutliforme refractory to standard initial therapy (radiotherapy and temozolomide), who were included on a phase II trial to demonstrate efficacy of perifosine plus temsirolimus. Three methods were being used to assess the efficacy of this treatment: clinical outcomes (aim 1), molecular analyses (aim 2), and advanced imaging analyses (aim 3).

other past support as co-investigator:

  1. S/N
    National Cancer Institute, NIH
    Subcellular Characterization of Diffuse Large B-Cell Lymphoma: Prediction of Treatment Response in Patients with and without underlying HIV infection. Following our previous results, we seek to improve the determination of prediction by the measurement of tumor phosphomonoesters using 31P MRS and the use of this prediction to norm treatment in DLBCL patients with and without underlying HIV infection.
  2. 1R21CA185801
    National Cancer Institute, NIH
    Interim MR Spectroscopic Imaging & Positron Emission Tomography to Norm Treatment in DLBCL. Exploratory grant where we seek to demonstrate if the use of an interim (during treatment) MRSI exam could be of use instead of an interim biopsy to increase the positive predictive value of the uptake of 18F-deoxyglucose (FDG) during treatment (interim) by positron emission tomography (i-PET) to risk-assign treatment in lymphoma patients.
     previous CV section